Anti-Cytolethal Distending Toxin B (Anti-CdtB)
Antibodies directed against cytolethal distending toxin B (CdtB), a bacterial enterotoxin produced by Campylobacter, Salmonella, and Shigella.
Standard vs. Optimal Reference RangesRatio
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<1.56 (optical density ratio)
General reference distribution across unselected commercial populations.
<1.00 (negative)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Bacterial CdtB mimics human vinculin via molecular mimicry, provoking cross-reactive autoimmune attack against enteric interstitial cells of Cajal.
Differential Diagnosis
Elevated Levels (Anti-CdtB High)
- •Post-infectious IBS (following bacterial gastroenteritis)
- •Small Intestinal Bacterial Overgrowth (SIBO) susceptibility
Low Levels (Anti-CdtB Low)
- •Non-infectious IBS
- •Intact gut motility pacemaker cells
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for Anti-CdtB
- Targeted organ system imaging or functional dynamic testing related to post-infectious ibs & bacterial toxins
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Anti-Cytolethal Distending Toxin B - The New England Journal of Medicine (2021). PMID: 33990124
- [2]Anti-CdtB Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35222901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-Cytolethal Distending Toxin B (Anti-CdtB) into overall healthspan optimization.